We are
not money managers, brokers, or fiduciaries
What that means is that
Porter & Co. is
a publisher only, and while we write about stocks, the stock market, businesses, and
investing
research, we do not provide personal or individual investment advice.
Porter & Co. does not, indeed cannot, ascertain
what investments
may be suitable for any individual investor. We do not know you and we cannot give
you advice. You
therefore agree, in subscribing and using our Services, that any recommendation we
make does not
constitute a recommendation that any security or strategy is suitable for you.
If you desire personalized investing advice, you
should engage a
registered investment adviser.
Only you can decide whether a particular security is
right for
you. You therefore
agree to be
solely and individually liable for any trades in which you engage using
information or
recommendations you learn from us.
We make mistakes and are not responsible for your
investing results.
Porter & Company, LLC (Porter & Co.) is a
publishing company
and the indicators, strategies, reports, articles and all other features of our
products are
provided for informational and educational purposes only and should not be construed
as personalized
investment advice.
Our recommendations and analysis are based on SEC
filings, current events, interviews, corporate press releases, and what we’ve
learned as financial
journalists.
While we do our best to ensure the accuracy of the
information we
rely on and provide, our work may contain errors. We recommend that our readers and
subscribers
independently research the companies in which they may invest, consult with an
investment
professional, and not make any investment decision based solely on our publications.
Refund policies
Refund policies will be explicit on all order forms
and order
confirmations.
We ask
that you carefully consider whether you want to subscribe to our Services, and
that once you do,
you honor your obligation to pay. We will consider refund requests on a
case-by-case basis, but
refunds are generally disfavored.
Conflicts of
Interest
Porter & Co. generally forbids its writers from
having a
financial interest in any security at the time they recommend to our subscribers;
should such a
financial interest exist, it will be disclosed in the publication in which the
security is
recommended.
All Porter & Co. employees and agents must wait
48 hours after
an initial trade recommendation is published on the Internet or after a direct mail
publication is
sent before acting on that recommendation.
Similarly, we are not paid or compensated in any way
by the
companies whose stocks we recommend.
PART 2: PROMOTION
DETAILS
Testimonials
Our testimonials are the words of real people
received in letters,
emails, and other feedback who have not been paid for their testimonials.
Testimonials are printed under aliases to protect
privacy and edited
for length. Their claims have not been independently verified or audited for
accuracy.
We do not know how much money may have been placed at
risk, what
portion of their total portfolio may have been allocated, or how long they may have
owned the
security. We do not claim that the results experienced by such subscribers are
typical and you will
likely have different results.
Past performance
does not guarantee
future results
Readers should be aware that trading stocks and all
other financial
instruments involves risk. Past performance is no guarantee of future results, and
we make no
representation that any customer will or is likely to achieve similar results.
Performance results of our recommendations prepared
by Porter &
Co. may not be based on actual trading of securities but instead may be based on a
hypothetical
trading account. Hypothetical performance results have many inherent limitations.
Your actual
results may vary.
You can call us for more information:
Lance James
Director of Customer Relations
1-888-610-8895
https://members.porterandcompanyresearch.com/wp-content/uploads/2023/10/TravelerLetter.pdf
https://assets.empirefinancialresearch.com/uploads/2023/10/Porter-Stansberry-letter-to-his-son-10-23.pdf
https://porterandcompanyresearch.atlassian.net/wiki/spaces/PCD/pages/10092584/Erez+Kalir+Claims
https://marketwise.box.com/s/v20nh4x7jc05s8bwg9tewos46cl99l68
https://finance.yahoo.com/quote/AXSM?p=AXSM&.tsrc=fin-srch
https://finance.yahoo.com/quote/SAVA?p=SAVA&.tsrc=fin-srch
https://www.nasdaq.com/articles/meet-the-biotech-stock-that-jumped-over-1000-in-one-day
https://porterandcompanyresearch.atlassian.net/wiki/spaces/PCD/pages/10092584/Erez+Kalir+Claims
https://www.inc.com/jeff-haden/putting-off-your-dreams-because-you-want-to-create-perfect-plan-why-steve-jobs-said-you-can-only-connect-dots-looking-backwards.html
https://marketwise.box.com/s/v20nh4x7jc05s8bwg9tewos46cl99l68
https://finance.yahoo.com/quote/DENN/key-statistics?p=DENN
https://finance.yahoo.com/quote/DDS/key-statistics?p=DDS
https://finance.yahoo.com/quote/MCD/key-statistics?p=MCD
https://finance.yahoo.com/quote/HSY/key-statistics?p=HSY
https://finance.yahoo.com/quote/LLY/key-statistics?p=LLY
https://finance.yahoo.com/quote/HSY/key-statistics?p=HSY
https://docs.google.com/document/d/1ndD1zzH70VbSC7jSViYj0z5YFS-eIcrW/edit
https://finance.yahoo.com/quote/LLY/key-statistics?p=LLY
https://www.marketwatch.com/investing/index/nquss4573?countrycode=xx&mod=search_symbol
https://site.warrington.ufl.edu/ritter/files/IPOs-LifeScience.pdf
https://www.wsj.com/articles/u-s-commits-2-billion-for-covid-19-vaccine-drug-supplies-11594132175
https://finance.yahoo.com/quote/NVAX/financials?p=NVAX
https://finance.yahoo.com/quote/NVAX/key-statistics?p=NVAX
https://www.tipranks.com/stocks/nvax/forecast
https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fda-clearance-pemvidutide-alt-801-ind
https://www.tipranks.com/stocks/alt/forecast
https://finance.yahoo.com/quote/ACHL/key-statistics?p=ACHL
https://www.wallstreetzen.com/stocks/us/nasdaq/achl/stock-forecast
https://money.cnn.com/quote/forecast/forecast.html?symb=ACHL
https://www.bankrate.com/banking/federal-reserve/fed-interest-rate-decision-biggest-winners/
https://www.cnbc.com/2023/12/13/fed-interest-rate-decision-december-2023.html
https://www.cnbc.com/2024/01/12/bill-ackman-sees-the-fed-moving-rapidly-on-interest-rate-cuts.html
https://www.fiercebiotech.com/biotech/capitulation-has-happened-investors-tepid-about-2024-after-year-ropes
https://www.rbccm.com/en/story/story.page?dcr=templatedata/article/story/data/2023/08/countdown-to-the-biotech-ma-explosion
https://www.barrons.com/articles/biotech-stocks-ma-deals-69736f2b
https://finance.yahoo.com/quote/VIR/key-statistics?p=VIR
https://finance.yahoo.com/quote/LYEL/key-statistics?p=LYEL
https://finance.yahoo.com/quote/NUVB/key-statistics?p=NUVB
https://finance.yahoo.com/quote/QURE/key-statistics?p=QURE
https://finance.yahoo.com/quote/STRO/key-statistics?p=STRO
https://finance.yahoo.com/quote/AVIR/key-statistics?p=AVIR
https://finance.yahoo.com/quote/KOD/key-statistics?p=KOD
https://finance.yahoo.com/quote/SGMT/key-statistics?p=SGMT
https://finance.yahoo.com/quote/ATHA/key-statistics?p=ATHA
https://finance.yahoo.com/quote/CYT/key-statistics?p=CYT
https://finance.yahoo.com/quote/VNDA?p=VNDA&.tsrc=fin-srch
https://finance.yahoo.com/quote/VNDA/key-statistics?p=VNDA
https://finance.yahoo.com/quote/VNDA/key-statistics/
https://www.vandapharma.com/pipeline/
https://seekingalpha.com/article/4641129-vanda-pharmaceuticals-value-in-the-biotech-space
https://www.crossrivertherapy.com/research/schizophrenia-statistics
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-that-us-food-and-drug-administration-accepts-new-drug-application-for-tradipitant-for-the-treatment-of-gastroparesis-302005177.html
https://hetlioz.com/
https://my.clevelandclinic.org/health/diseases/12119-insomnia
https://seekingalpha.com/article/4641129-vanda-pharmaceuticals-value-in-the-biotech-space
https://www.marketwatch.com/investing/stock/vnda/financials?mod=mw_quote_tab
https://www.macrotrends.net/stocks/charts/VNDA/vanda-pharmaceuticals/revenue
https://www.nbcnews.com/health/health-news/fda-approves-cure-sickle-cell-disease-first-treatment-use-gene-editing-rcna127979
https://www.nhlbi.nih.gov/health/sickle-cell-disease
https://www.barrons.com/articles/bluebird-bio-stock-offering-price-down-93fde066
https://finance.yahoo.com/quote/BLUE/financials?p=BLUE
https://www.tipranks.com/stocks/blue/forecast
https://finance.yahoo.com/quote/KZR/key-statistics?p=KZR
https://www.tipranks.com/stocks/kzr/forecast
https://www.gilead.com/news-and-press/press-room/press-releases/2021/1/gilead-and-vir-biotechnology-establish-clinical-collaboration-to-explore-combination-strategies-for-functional-cure-for-chronic-hepatitis-b-virus
https://www.hepb.org/research-and-programs/300-million-reasons-campaign/
https://finance.yahoo.com/news/vir-biotechnology-present-data-ongoing-130000820.html
https://www.gurufocus.com/insider/127756/arch-venture-fund-ix,-l.p.
https://www.gurufocus.com/insider/127756/arch-venture-fund-ix,-l.p.
https://finance.yahoo.com/quote/VIR/key-statistics?p=VIR
https://www.tipranks.com/stocks/vir/forecast
https://www.genengnews.com/gen-edge/the-unbearable-cost-of-drug-development-deloitte-report-shows-15-jump-in-rd-to-2-3-billion/#:~:text=to%20%242.3%20Billion-,The%20Unbearable%20Cost%20of%20Drug%20Development%3A%20Deloitte%20Report%20Shows%2015,in%20R%26D%20to%20%242.3%20Billion&text=A%20pair%20of%20recently%2Dreleased,billion%20per%20therapy%20on%20average.
https://medwatch.com/News/Pharma___Biotech/article14171253.ece
https://porterandcompanyresearch.atlassian.net/wiki/spaces/PCD/pages/10321928/Porter+Stansberry+Predictions
https://porterandcompanyresearch.atlassian.net/wiki/spaces/PCD/pages/10321928/Porter+Stansberry+Predictions
https://www.sangamo.com/programs/
https://finance.yahoo.com/quote/SGMO/financials?p=SGMO
https://fabrydiseasenews.com/news/top-10-stories-2023-fabry-disease-marked-treatment-news/
https://finance.yahoo.com/quote/SGMO?p=SGMO&.tsrc=fin-srch
https://finance.yahoo.com/quote/SGMO/key-statistics?p=SGMO
https://www.tipranks.com/stocks/sgmo/forecast
https://finance.yahoo.com/news/industry-analysts-just-upgraded-sangamo-110413043.html
https://www.affimed.com/our-ice-molecules-and-the-cancers-they-target/
https://finance.yahoo.com/quote/AFMD/key-statistics?p=AFMD
https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-announces-us-fda-fast-track-designation-0
https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-announces-positive-initial-data-phase-2
https://finance.yahoo.com/quote/AVIR/key-statistics?p=AVIR
https://ateapharma.com/covid-19/bemnifosbuvir/
https://www.nytimes.com/2008/10/29/business/29biotech.html
https://porterandcompanyresearch.atlassian.net/wiki/spaces/PCD/pages/10059824/Stansberry+Research+Track+Records
https://marketwise.box.com/s/gsl5cchppt8ej3r9gtfygyktme83lo9m
https://www.nichd.nih.gov/grants-contracts/SBIR_STTR/showcase/Elagolix
https://www.cedars-sinai.org/blog/coping-with-endometriosis.html
https://www.marketwatch.com/investing/stock/nbix/charts?mod=mw_quote_advanced
https://members.stansberryresearch.com/articles/stansberrys-investment-advisory/how-to-profit-from-a-weight-loss-breakthrough
https://members.stansberryresearch.com/articles/phase-1-investor/how-to-profit-from-blockbuster-drug-discoveries-without-taking-big-risks-2
https://members.stansberryresearch.com/articles/stansberry-innovations-report/when-nature-meets-novelty
https://www.marketwatch.com/investing/stock/ntla?mod=mw_quote_switch
https://members.porterandcompanyresearch.com/fake-money-and-another-global-epidemic/
https://finance.yahoo.com/news/lyell-immunopharma-receives-fda-orphan-210500516.html
https://finance.yahoo.com/quote/LYEL/key-statistics?p=LYEL
https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-receives-fda-orphan-drug-designation-lyl845
https://www.bizjournals.com/sanfrancisco/news/2023/03/03/lynn-seely-lyell-immunopharma-myovant-sciences.html
https://www.cbinsights.com/investor/richard-klausner
https://www.tipranks.com/stocks/lyel/forecast
https://finance.yahoo.com/quote/NUVB/key-statistics?p=NUVB
https://www.tipranks.com/stocks/nuvb/forecast
https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/
https://atelfo.github.io/2023/02/26/pharmaceutical-blockbusters-the-past-present-and-future.html
https://atelfo.github.io/2023/02/26/pharmaceutical-blockbusters-the-past-present-and-future.html
https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals/
https://www.capsahealthcare.com/the-rapid-expansion-of-central-filling-mail-order-pharmacies/
https://www.biospace.com/article/biotech-bankruptcies-skyrocket/
https://www.healthline.com/health-news/fda-approves-drug-hair-loss-treatment-for-alopecia
https://www.fiercebiotech.com/biotech/pfizer-s-ritlecitinib-hits-goal-alopecia-phase-3-setting-up-showdown-lilly
https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata
https://medicine.wustl.edu/news/what-to-know-about-the-new-alzheimers-drug-leqembi/
https://www.pharmaceutical-technology.com/features/pharma-breakthroughs-10-novel-drug-approvals-that-made-headlines-in-2023/?cf-view
https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2023.09.9.56#:~:text=In%20August%2C%20the%20Food%20and,affect%201%20in%208%20women.
https://www.marketwatch.com/investing/stock/sage/charts?mod=mw_quote_advanced
https://www.zepbound.lilly.com/hcp/getting-patients-started?gclid=Cj0KCQiAnrOtBhDIARIsAFsSe53Q47MP0ly3a-0SMMcp8gbgJkndEN7rKbo3tUNYzjWduMX7aDLNjIoaAqPHEALw_wcB
https://www.nbcnews.com/health/health-news/zepbound-eli-lilly-weight-loss-drug-what-to-know-rcna124237
https://www.today.com/health/diet-fitness/weight-loss-drugs-guide-rcna131852
https://www.bloomberg.com/news/articles/2023-12-05/zepbound-weight-loss-drug-now-on-sale-to-rival-hard-to-find-wegovy
https://www.bloomberg.com/news/articles/2023-12-05/zepbound-weight-loss-drug-now-on-sale-to-rival-hard-to-find-wegovy
https://www.statista.com/statistics/258010/top-branded-drugs-based-on-retail-sales-in-the-us/
https://time.com/6333255/fda-approval-zepbound-tirzepatide-mounjaro-weight-loss/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
https://skift.com/2023/07/13/7-facts-about-royal-caribbeans-new-icon-of-the-seas/
https://itrexgroup.com/blog/why-use-ai-in-pharma-and-how-to-get-it-right/
https://www.prnewswire.com/news-releases/milliporesigma-launches-first-ever-ai-solution-to-integrate-drug-discovery-and-synthesis-302003268.html
https://averyfairbank.com/using-ai-for-drug-discovery-could-cut-costs-by-as-much-as-70-is-ai-worth-the-hype/
https://www.prnewswire.com/news-releases/milliporesigma-launches-first-ever-ai-solution-to-integrate-drug-discovery-and-synthesis-302003268.html
https://www.pharmaceuticalprocessingworld.com/ai-pharma-drug-development-billion-opportunity/
https://www.labiotech.eu/best-biotech/ai-drug-discovery-companies/#insilicomedicine
https://www.bio-itworld.com/news/2024/01/03/trendspotting-what-s-coming-for-biotech-in-2024
https://zipdo.co/statistics/ai-in-pharmaceutical-industry/
https://www.databridgemarketresearch.com/reports/global-artificial-intelligence-ai-in-drug-discovery-market
https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-drug-discovery-market
https://www.wsj.com/tech/ai/artificial-intelligence-medicine-innovation-6739b4f8
https://archive.ph/kD2C3
https://newsite.schrodinger.com/company/team/
https://golden.com/wiki/Schrodinger-K46DM88
https://cen.acs.org/articles/89/i32/Taking-Big-Step-Virtual-Space.html
https://www.nanalyze.com/2023/03/schrodinger-stock-drug-discovery-platform/
https://www.nanalyze.com/2023/03/schrodinger-stock-drug-discovery-platform/
https://www.nasdaq.com/articles/schrodinger-is-an-ai-powered-drug-discovery-developer-to-watch
https://stockanalysis.com/stocks/sdgr/revenue/
https://www.macrotrends.net/stocks/charts/SDGR/schrodinger/financial-statements
https://newsite.schrodinger.com/pipeline/
https://www.nasdaq.com/articles/2-reasons-to-buy-recursion-pharmaceuticals-and-1-reason-to-sell
https://archive.ph/z4xrr#selection-2427.0-2427.244
https://archive.ph/z4xrr#selection-2305.1-2309.63
https://www.theguardian.com/business/2022/jul/30/andrew-hopkins-of-exscientia-the-man-using-ai-to-cure-disease
https://investorplace.com/2023/05/3-pharma-stocks-that-will-boom-thanks-to-ai/
https://www.macrotrends.net/stocks/charts/SDGR/schrodinger/revenue
https://www.macrotrends.net/stocks/charts/RXRX/recursion-pharmaceuticals/revenue
https://www.macrotrends.net/stocks/charts/EXAI/exscientia/revenue
https://staging.hedgeweek.com/hedge-funds-hunt-bargain-biotech-stocks/
https://www.wsj.com/finance/investing/its-biotech-stocks-time-to-shine-7eb26f83
https://archive.ph/Pzv0Y#selection-4509.121-4509.176
https://fundselectorasia.com/biotech-sector-is-ripe-with-alpha-janus-henderson/
https://www.janushenderson.com/en-us/advisor/bio/agustin-mohedas-ph-d/
https://members.stansberryresearch.com/articles/retirement-millionaire/the-seven-real-secrets-of-the-worlds-best-investors-2
https://www.investorsobserver.com/news/stock-update/is-soleno-therapeutics-inc-slno-stock-at-the-top-of-the-biotechnology-industry
https://www.fool.com/investing/2019/01/14/why-amarin-stock-skyrocketed-239-in-2018-and-is-up.aspx
https://www.fiercepharma.com/pharma/amarin-s-vascepa-patent-defense-ends-a-loss-at-supreme-court
https://members.porterandcompanyresearch.com/distressed-investing-portfolio/